Aeterna Zentaris Pens Licensing and Development Agreement for Oral COVID-19 Vaccine

Aeterna Zentaris has entered a global licensing agreement for an oral COVID-19 vaccine candidate created at Würzburg, Germany’s Julius-Maximilians-University Würzburg.

They technology, which has already led to an approved typhoid fever vaccine, could potentially lead to an orally active, live-attenuated bacterial vaccine for preventing COVID-19 infection.

The company aims to develop the vaccine to provide an improved immune response to viral variants and to have simple storage and logistics requirements.